Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year

Detalhes bibliográficos
Autor(a) principal: Wu,Yao
Data de Publicação: 2018
Outros Autores: Si,Feifei, Luo,Li, Yi,Qijian
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal de Pediatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572018000400446
Resumo: Abstract Objective: Melatonin has a protective role in adults with cardiovascular disease, but the effects of melatonin in children with cardiac dysfunction are not well understood. This study was designed to explore the variations in melatonin, myeloperoxidase, and caspase-3 levels in children suffering from heart failure. Methods: Seventy-two pediatric patients with heart failure and twelve healthy children were enrolled in this study. A modified Ross scoring system was used to evaluate clinical cardiac function. Patients with a score of >2 points were included in the study and were divided into three groups according to severity of heart failure: mild (score: 3-6), moderate (score: 7-9), and severe (score: 10-12). Echocardiographic parameters, laboratory data, and serum levels of melatonin, myeloperoxidase, and caspase-3 were measured and analyzed in all patients. Results: Compared with patients with mild and moderate heart failure, patients in the severe heart failure group had significantly decreased left ventricular ejection fraction (p < 0.001), and significantly increased serum melatonin levels (p = 0.013) and myeloperoxidase levels (p < 0.001). Serum melatonin levels were positively correlated with serum caspase-3 levels (p < 0.001). The optimal cutoff values of serum melatonin levels for the diagnosis of severe heart failure and primary cardiomyopathy in pediatric patients with heart failure were 54.14 pg/mL and 32.88 pg/mL, respectively. Conclusions: Serum melatonin and myeloperoxidase levels were increased in children with severe heart failure. It is likely that increasing melatonin levels may act as a compensatory mechanism in pediatric children with heart failure.
id SBPE-1_7db7a65f103f0d336bfec2acf2b4037b
oai_identifier_str oai:scielo:S0021-75572018000400446
network_acronym_str SBPE-1
network_name_str Jornal de Pediatria (Online)
repository_id_str
spelling Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 yearMelatoninMyeloperoxidaseCapsase-3Heart failurePediatric patientsAbstract Objective: Melatonin has a protective role in adults with cardiovascular disease, but the effects of melatonin in children with cardiac dysfunction are not well understood. This study was designed to explore the variations in melatonin, myeloperoxidase, and caspase-3 levels in children suffering from heart failure. Methods: Seventy-two pediatric patients with heart failure and twelve healthy children were enrolled in this study. A modified Ross scoring system was used to evaluate clinical cardiac function. Patients with a score of >2 points were included in the study and were divided into three groups according to severity of heart failure: mild (score: 3-6), moderate (score: 7-9), and severe (score: 10-12). Echocardiographic parameters, laboratory data, and serum levels of melatonin, myeloperoxidase, and caspase-3 were measured and analyzed in all patients. Results: Compared with patients with mild and moderate heart failure, patients in the severe heart failure group had significantly decreased left ventricular ejection fraction (p < 0.001), and significantly increased serum melatonin levels (p = 0.013) and myeloperoxidase levels (p < 0.001). Serum melatonin levels were positively correlated with serum caspase-3 levels (p < 0.001). The optimal cutoff values of serum melatonin levels for the diagnosis of severe heart failure and primary cardiomyopathy in pediatric patients with heart failure were 54.14 pg/mL and 32.88 pg/mL, respectively. Conclusions: Serum melatonin and myeloperoxidase levels were increased in children with severe heart failure. It is likely that increasing melatonin levels may act as a compensatory mechanism in pediatric children with heart failure.Sociedade Brasileira de Pediatria2018-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572018000400446Jornal de Pediatria v.94 n.4 2018reponame:Jornal de Pediatria (Online)instname:Sociedade Brasileira de Pediatria (SBP)instacron:SBPE10.1016/j.jped.2017.06.023info:eu-repo/semantics/openAccessWu,YaoSi,FeifeiLuo,LiYi,Qijianeng2018-08-16T00:00:00Zoai:scielo:S0021-75572018000400446Revistahttp://www.jped.com.br/https://old.scielo.br/oai/scielo-oai.php||jped@jped.com.br1678-47820021-7557opendoar:2018-08-16T00:00Jornal de Pediatria (Online) - Sociedade Brasileira de Pediatria (SBP)false
dc.title.none.fl_str_mv Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
title Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
spellingShingle Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
Wu,Yao
Melatonin
Myeloperoxidase
Capsase-3
Heart failure
Pediatric patients
title_short Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
title_full Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
title_fullStr Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
title_full_unstemmed Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
title_sort Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
author Wu,Yao
author_facet Wu,Yao
Si,Feifei
Luo,Li
Yi,Qijian
author_role author
author2 Si,Feifei
Luo,Li
Yi,Qijian
author2_role author
author
author
dc.contributor.author.fl_str_mv Wu,Yao
Si,Feifei
Luo,Li
Yi,Qijian
dc.subject.por.fl_str_mv Melatonin
Myeloperoxidase
Capsase-3
Heart failure
Pediatric patients
topic Melatonin
Myeloperoxidase
Capsase-3
Heart failure
Pediatric patients
description Abstract Objective: Melatonin has a protective role in adults with cardiovascular disease, but the effects of melatonin in children with cardiac dysfunction are not well understood. This study was designed to explore the variations in melatonin, myeloperoxidase, and caspase-3 levels in children suffering from heart failure. Methods: Seventy-two pediatric patients with heart failure and twelve healthy children were enrolled in this study. A modified Ross scoring system was used to evaluate clinical cardiac function. Patients with a score of >2 points were included in the study and were divided into three groups according to severity of heart failure: mild (score: 3-6), moderate (score: 7-9), and severe (score: 10-12). Echocardiographic parameters, laboratory data, and serum levels of melatonin, myeloperoxidase, and caspase-3 were measured and analyzed in all patients. Results: Compared with patients with mild and moderate heart failure, patients in the severe heart failure group had significantly decreased left ventricular ejection fraction (p < 0.001), and significantly increased serum melatonin levels (p = 0.013) and myeloperoxidase levels (p < 0.001). Serum melatonin levels were positively correlated with serum caspase-3 levels (p < 0.001). The optimal cutoff values of serum melatonin levels for the diagnosis of severe heart failure and primary cardiomyopathy in pediatric patients with heart failure were 54.14 pg/mL and 32.88 pg/mL, respectively. Conclusions: Serum melatonin and myeloperoxidase levels were increased in children with severe heart failure. It is likely that increasing melatonin levels may act as a compensatory mechanism in pediatric children with heart failure.
publishDate 2018
dc.date.none.fl_str_mv 2018-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572018000400446
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572018000400446
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.jped.2017.06.023
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Pediatria
publisher.none.fl_str_mv Sociedade Brasileira de Pediatria
dc.source.none.fl_str_mv Jornal de Pediatria v.94 n.4 2018
reponame:Jornal de Pediatria (Online)
instname:Sociedade Brasileira de Pediatria (SBP)
instacron:SBPE
instname_str Sociedade Brasileira de Pediatria (SBP)
instacron_str SBPE
institution SBPE
reponame_str Jornal de Pediatria (Online)
collection Jornal de Pediatria (Online)
repository.name.fl_str_mv Jornal de Pediatria (Online) - Sociedade Brasileira de Pediatria (SBP)
repository.mail.fl_str_mv ||jped@jped.com.br
_version_ 1752122321436409856